Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed Feb 16, 2021 · 10-Q · 47 days after period end · 0001731122-21-000261
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Net Income | -$7.86M | -$6.59M | -$6.92M | -$4.06M |
| EPS Diluted | -$0.12 | -$0.12 | -$0.15 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Feb 16, 2021 · 47 d after period end
